Omnia Biosystems is a precision medicine company founded in 2021 with a mission to revolutionise cancer diagnosis and treatment through the power of data. Our cloud-based software provides healthcare professionals with a comprehensive and holistic view of patient data, enabling them to make more informed and accurate diagnoses and treatment decisions.
Our Patient Specific, AI-Enabled, Biomarker Driven platform utilises advanced algorithms to analyse genomic data, identifying specific gene mutations or biomarkers in a patient's cancer. This information allows healthcare providers to select targeted therapies that are more likely to be effective, leading to better patient outcomes and reduced healthcare costs.
In addition, our software supports both umbrella and basket trial designs, allowing for efficient and accurate patient selection and treatment. This innovative approach to clinical trial design has the potential to accelerate drug development and improve patient outcomes.
At Omnia Biosystems, we are committed to advancing precision medicine and improving patient outcomes. Our team of experienced scientists, clinicians, and technologists are dedicated to developing cutting-edge solutions that will transform the way we diagnose and treat cancer. We are excited to continue pushing the boundaries of what is possible and to help usher in a new era of personalised cancer care.